ID   DNM3A_MOUSE             Reviewed;         908 AA.
AC   O88508; Q3TZK8; Q3UH24; Q8CJ60; Q922J0; Q9CSE1;
DT   26-SEP-2001, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 2.
DT   22-JUL-2015, entry version 157.
DE   RecName: Full=DNA (cytosine-5)-methyltransferase 3A;
DE            Short=Dnmt3a;
DE            EC=2.1.1.37;
DE   AltName: Full=DNA methyltransferase MmuIIIA;
DE            Short=DNA MTase MmuIIIA;
DE            Short=M.MmuIIIA;
GN   Name=Dnmt3a;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Glires; Rodentia; Sciurognathi;
OC   Muroidea; Muridae; Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RX   PubMed=9662389; DOI=10.1038/890;
RA   Okano M., Xie S., Li E.;
RT   "Cloning and characterization of a family of novel mammalian DNA
RT   (cytosine-5) methyltransferases.";
RL   Nat. Genet. 19:219-220(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Mammary gland;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   STRAIN=C57BL/6, and C57BL/6J; TISSUE=Brain, Embryo, and Skin;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M.,
RA   Davis M.J., Wilming L.G., Aidinis V., Allen J.E.,
RA   Ambesi-Impiombato A., Apweiler R., Aturaliya R.N., Bailey T.L.,
RA   Bansal M., Baxter L., Beisel K.W., Bersano T., Bono H., Chalk A.M.,
RA   Chiu K.P., Choudhary V., Christoffels A., Clutterbuck D.R.,
RA   Crowe M.L., Dalla E., Dalrymple B.P., de Bono B., Della Gatta G.,
RA   di Bernardo D., Down T., Engstrom P., Fagiolini M., Faulkner G.,
RA   Fletcher C.F., Fukushima T., Furuno M., Futaki S., Gariboldi M.,
RA   Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N.,
RA   Hill D., Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T.,
RA   Jakt M., Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H.,
RA   Kitano H., Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K.,
RA   Kurochkin I.V., Lareau L.F., Lazarevic D., Lipovich L., Liu J.,
RA   Liuni S., McWilliam S., Madan Babu M., Madera M., Marchionni L.,
RA   Matsuda H., Matsuzawa S., Miki H., Mignone F., Miyake S., Morris K.,
RA   Mottagui-Tabar S., Mulder N., Nakano N., Nakauchi H., Ng P.,
RA   Nilsson R., Nishiguchi S., Nishikawa S., Nori F., Ohara O.,
RA   Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G., Pesole G.,
RA   Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z., Ringwald M.,
RA   Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B.,
RA   Sperling S., Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K.,
RA   Tammoja K., Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A.,
RA   Ueda H.R., van Nimwegen E., Verardo R., Wei C.L., Yagi K.,
RA   Yamanishi H., Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C.,
RA   Grimmond S.M., Teasdale R.D., Liu E.T., Brusic V., Quackenbush J.,
RA   Wahlestedt C., Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y.,
RA   Fukuda S., Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T.,
RA   Iida J., Imamura K., Itoh M., Kato T., Kawaji H., Kawagashira N.,
RA   Kawashima T., Kojima M., Kondo S., Konno H., Nakano K., Ninomiya N.,
RA   Nishio T., Okada M., Plessy C., Shibata K., Shiraki T., Suzuki S.,
RA   Tagami M., Waki K., Watahiki A., Okamura-Oho Y., Suzuki H., Kawai J.,
RA   Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), SUBCELLULAR LOCATION,
RP   ALTERNATIVE PROMOTER USAGE, AND TISSUE SPECIFICITY.
RC   STRAIN=129/SvJ;
RX   PubMed=12138111; DOI=10.1074/jbc.M205312200;
RA   Chen T., Ueda Y., Xie S., Li E.;
RT   "A novel Dnmt3a isoform produced from an alternative promoter
RT   localizes to euchromatin and its expression correlates with active de
RT   novo methylation.";
RL   J. Biol. Chem. 277:38746-38754(2002).
RN   [5]
RP   FUNCTION, AND DEVELOPMENTAL STAGE.
RX   PubMed=10555141; DOI=10.1016/S0092-8674(00)81656-6;
RA   Okano M., Bell D.W., Haber D.A., Li E.;
RT   "DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo
RT   methylation and mammalian development.";
RL   Cell 99:247-257(1999).
RN   [6]
RP   FUNCTION.
RX   PubMed=11399089; DOI=10.1006/jmbi.2001.4710;
RA   Gowher H., Jeltsch A.;
RT   "Enzymatic properties of recombinant Dnmt3a DNA methyltransferase from
RT   mouse: the enzyme modifies DNA in a non-processive manner and also
RT   methylates non-CpG correction sites.";
RL   J. Mol. Biol. 309:1201-1208(2001).
RN   [7]
RP   ERRATUM.
RA   Gowher H., Jeltsch A.;
RL   J. Mol. Biol. 310:951-951(2001).
RN   [8]
RP   FUNCTION, AND INTERACTION WITH ZBTB18 AND HDAC1.
RX   PubMed=11350943; DOI=10.1093/emboj/20.10.2536;
RA   Fuks F., Burgers W.A., Godin N., Kasai M., Kouzarides T.;
RT   "Dnmt3a binds deacetylases and is recruited by a sequence-specific
RT   repressor to silence transcription.";
RL   EMBO J. 20:2536-2544(2001).
RN   [9]
RP   FUNCTION.
RX   PubMed=11919202; DOI=10.1074/jbc.M202148200;
RA   Gowher H., Jeltsch A.;
RT   "Molecular enzymology of the catalytic domains of the Dnmt3a and
RT   Dnmt3b DNA methyltransferases.";
RL   J. Biol. Chem. 277:20409-20414(2002).
RN   [10]
RP   IDENTIFICATION IN A COMPLEX WITH HDAC1.
RX   PubMed=12616525; DOI=10.1002/jcb.10457;
RA   Datta J., Ghoshal K., Sharma S.M., Tajima S., Jacob S.T.;
RT   "Biochemical fractionation reveals association of DNA
RT   methyltransferase (Dnmt) 3b with Dnmt1 and that of Dnmt 3a with a
RT   histone H3 methyltransferase and Hdac1.";
RL   J. Cell. Biochem. 88:855-864(2003).
RN   [11]
RP   SUBCELLULAR LOCATION, AND MUTAGENESIS OF 302-VAL-PRO-303 AND
RP   705-PRO-CYS-706.
RX   PubMed=15456878; DOI=10.1128/MCB.24.20.9048-9058.2004;
RA   Chen T., Tsujimoto N., Li E.;
RT   "The PWWP domain of Dnmt3a and Dnmt3b is required for directing DNA
RT   methylation to the major satellite repeats at pericentric
RT   heterochromatin.";
RL   Mol. Cell. Biol. 24:9048-9058(2004).
RN   [12]
RP   FUNCTION.
RX   PubMed=15215868; DOI=10.1038/nature02633;
RA   Kaneda M., Okano M., Hata K., Sado T., Tsujimoto N., Li E., Sasaki H.;
RT   "Essential role for de novo DNA methyltransferase Dnmt3a in paternal
RT   and maternal imprinting.";
RL   Nature 429:900-903(2004).
RN   [13]
RP   SUMOYLATION, AND INTERACTION WITH UBC9; PIAS1 AND PIAS2.
RX   PubMed=14752048; DOI=10.1093/nar/gkh195;
RA   Ling Y., Sankpal U.T., Robertson A.K., McNally J.G., Karpova T.,
RA   Robertson K.D.;
RT   "Modification of de novo DNA methyltransferase 3a (Dnmt3a) by SUMO-1
RT   modulates its interaction with histone deacetylases (HDACs) and its
RT   capacity to repress transcription.";
RL   Nucleic Acids Res. 32:598-610(2004).
RN   [14]
RP   ENZYME REGULATION.
RX   PubMed=15671018; DOI=10.1074/jbc.M413412200;
RA   Gowher H., Liebert K., Hermann A., Xu G., Jeltsch A.;
RT   "Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B
RT   DNA-(cytosine-C5)-methyltransferases by Dnmt3L.";
RL   J. Biol. Chem. 280:13341-13348(2005).
RN   [15]
RP   FUNCTION.
RX   PubMed=16567415; DOI=10.1093/jb/mvj044;
RA   Takeshima H., Suetake I., Shimahara H., Ura K., Tate S., Tajima S.;
RT   "Distinct DNA methylation activity of Dnmt3a and Dnmt3b towards naked
RT   and nucleosomal DNA.";
RL   J. Biochem. 139:503-515(2006).
RN   [16]
RP   MUTAGENESIS OF PHE-636; GLU-660; ASP-682; CYS-706; ASN-707; SER-710;
RP   ARG-716; LYS-717; GLU-752; ASN-753; ARG-788; ARG-827; ARG-832;
RP   ARG-878; ARG-881 AND ARG-883.
RX   PubMed=16472822; DOI=10.1016/j.jmb.2006.01.035;
RA   Gowher H., Loutchanwoot P., Vorobjeva O., Handa V., Jurkowska R.Z.,
RA   Jurkowski T.P., Jeltsch A.;
RT   "Mutational analysis of the catalytic domain of the murine Dnmt3a DNA-
RT   (cytosine C5)-methyltransferase.";
RL   J. Mol. Biol. 357:928-941(2006).
RN   [17]
RP   INTERACTION WITH THE PRC2/EED-EZH2 COMPLEX.
RX   PubMed=16357870; DOI=10.1038/nature04431;
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RT   "The Polycomb group protein EZH2 directly controls DNA methylation.";
RL   Nature 439:871-874(2006).
RN   [18]
RP   ERRATUM.
RA   Vire E., Brenner C., Deplus R., Blanchon L., Fraga M., Didelot C.,
RA   Morey L., Van Eynde A., Bernard D., Vanderwinden J.-M., Bollen M.,
RA   Esteller M., Di Croce L., de Launoit Y., Fuks F.;
RL   Nature 446:824-824(2006).
RN   [19]
RP   FUNCTION, ENZYME REGULATION, AND MUTAGENESIS OF PHE-728.
RX   PubMed=17713477; DOI=10.1038/nature06146;
RA   Jia D., Jurkowska R.Z., Zhang X., Jeltsch A., Cheng X.;
RT   "Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA
RT   methylation.";
RL   Nature 449:248-251(2007).
RN   [20]
RP   FUNCTION.
RX   PubMed=18823905; DOI=10.1016/j.jmb.2008.03.001;
RA   Takeshima H., Suetake I., Tajima S.;
RT   "Mouse Dnmt3a preferentially methylates linker DNA and is inhibited by
RT   histone H1.";
RL   J. Mol. Biol. 383:810-821(2008).
RN   [21]
RP   INTERACTION WITH UHRF1.
RX   PubMed=19798101; DOI=10.1038/embor.2009.201;
RA   Meilinger D., Fellinger K., Bultmann S., Rothbauer U., Bonapace I.M.,
RA   Klinkert W.E., Spada F., Leonhardt H.;
RT   "Np95 interacts with de novo DNA methyltransferases, Dnmt3a and
RT   Dnmt3b, and mediates epigenetic silencing of the viral CMV promoter in
RT   embryonic stem cells.";
RL   EMBO Rep. 10:1259-1264(2009).
RN   [22]
RP   SUBCELLULAR LOCATION.
RX   PubMed=20547484; DOI=10.1074/jbc.M109.089433;
RA   Dhayalan A., Rajavelu A., Rathert P., Tamas R., Jurkowska R.Z.,
RA   Ragozin S., Jeltsch A.;
RT   "The Dnmt3a PWWP domain reads histone 3 lysine 36 trimethylation and
RT   guides DNA methylation.";
RL   J. Biol. Chem. 285:26114-26120(2010).
CC   -!- FUNCTION: Required for genome-wide de novo methylation and is
CC       essential for the establishment of DNA methylation patterns during
CC       development. DNA methylation is coordinated with methylation of
CC       histones. It modifies DNA in a non-processive manner and also
CC       methylates non-CpG sites. May preferentially methylate DNA linker
CC       between 2 nucleosomal cores and is inhibited by histone H1. Plays
CC       a role in paternal and maternal imprinting. Required for
CC       methylation of most imprinted loci in germ cells. Acts as a
CC       transcriptional corepressor for ZBTB18. Recruited to trimethylated
CC       'Lys-36' of histone H3 (H3K36me3) sites. Can actively repress
CC       transcription through the recruitment of HDAC activity.
CC       {ECO:0000269|PubMed:10555141, ECO:0000269|PubMed:11350943,
CC       ECO:0000269|PubMed:11399089, ECO:0000269|PubMed:11919202,
CC       ECO:0000269|PubMed:15215868, ECO:0000269|PubMed:16567415,
CC       ECO:0000269|PubMed:17713477, ECO:0000269|PubMed:18823905}.
CC   -!- CATALYTIC ACTIVITY: S-adenosyl-L-methionine + DNA = S-adenosyl-L-
CC       homocysteine + DNA containing 5-methylcytosine.
CC       {ECO:0000255|PROSITE-ProRule:PRU10018}.
CC   -!- ENZYME REGULATION: Activated by binding to the regulatory factor
CC       DNMT3L. {ECO:0000269|PubMed:15671018,
CC       ECO:0000269|PubMed:17713477}.
CC   -!- SUBUNIT: Heterotetramer composed of 1 DNMT3A homodimer and 2
CC       DNMT3L subunits (DNMT3L-DNMT3A-DNMT3A-DNMT3L). Interacts with
CC       DNMT1 and DNMT3B. Interacts with MPHOSPH8. Interacts with histone
CC       H3 that is not methylated at 'Lys-4' (H3K4) (By similarity). Binds
CC       the ZBTB18 transcriptional repressor. Interacts with SETDB1.
CC       Associates with HDAC1 through its ADD domain. Interacts with the
CC       PRC2/EED-EZH2 complex. Interacts with UBC9, PIAS1 and PIAS2.
CC       {ECO:0000250, ECO:0000269|PubMed:11350943,
CC       ECO:0000269|PubMed:12616525, ECO:0000269|PubMed:14752048,
CC       ECO:0000269|PubMed:16357870, ECO:0000269|PubMed:19798101}.
CC   -!- INTERACTION:
CC       Q9CWR8:Dnmt3l; NbExp=6; IntAct=EBI-995154, EBI-3043871;
CC       Q60848:Hells; NbExp=4; IntAct=EBI-995154, EBI-3043887;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:12138111,
CC       ECO:0000269|PubMed:15456878, ECO:0000269|PubMed:20547484}.
CC       Cytoplasm {ECO:0000250}. Note=Accumulates in the major satellite
CC       repeats at pericentric heterochromatin.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative promoter usage; Named isoforms=2;
CC       Name=1;
CC         IsoId=O88508-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O88508-2; Sequence=VSP_009423;
CC   -!- TISSUE SPECIFICITY: Isoform 1 is expressed ubiquitously at low
CC       levels. Expression of isoform 2 is restricted to tissues
CC       containing cells which are undergoing active de novo methylation,
CC       including spleen, testis and thymus.
CC       {ECO:0000269|PubMed:12138111}.
CC   -!- DEVELOPMENTAL STAGE: At E7.5, the protein is moderately expressed
CC       in embryonic ectoderm and weakly in mesodermal cells. At E8.5 and
CC       E9.5, the expression become ubiquitous with an increase in the
CC       somites and in the ventral part of the embryo.
CC       {ECO:0000269|PubMed:10555141}.
CC   -!- DOMAIN: The PWWP domain is essential for targeting to pericentric
CC       heterochromatin. It specifically recognizes and binds
CC       trimethylated 'Lys-36' of histone H3 (H3K36me3) (PubMed:20547484).
CC       {ECO:0000269|PubMed:20547484}.
CC   -!- PTM: Sumoylated; sumoylation disrupts the ability to interact with
CC       histone deacetylases (HDAC1 and HDAC2) and repress transcription.
CC       {ECO:0000269|PubMed:14752048}.
CC   -!- SIMILARITY: Belongs to the class I-like SAM-binding
CC       methyltransferase superfamily. C5-methyltransferase family.
CC       {ECO:0000255|PROSITE-ProRule:PRU01016}.
CC   -!- SIMILARITY: Contains 1 ADD domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00865}.
CC   -!- SIMILARITY: Contains 1 GATA-type zinc finger.
CC       {ECO:0000255|PROSITE-ProRule:PRU00865}.
CC   -!- SIMILARITY: Contains 1 PHD-type zinc finger. {ECO:0000255|PROSITE-
CC       ProRule:PRU00865}.
CC   -!- SIMILARITY: Contains 1 PWWP domain. {ECO:0000255|PROSITE-
CC       ProRule:PRU00162}.
CC   -!- SIMILARITY: Contains 1 SAM-dependent MTase C5-type domain.
CC       {ECO:0000255|PROSITE-ProRule:PRU01016}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAB28644.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF068625; AAC40177.2; -; mRNA.
DR   EMBL; AF480164; AAN40038.1; -; mRNA.
DR   EMBL; AK013096; BAB28644.2; ALT_INIT; mRNA.
DR   EMBL; AK090132; BAC41110.1; -; mRNA.
DR   EMBL; AK147263; BAE27806.1; -; mRNA.
DR   EMBL; AK147627; BAE28033.1; -; mRNA.
DR   EMBL; AK147642; BAE28043.1; -; mRNA.
DR   EMBL; AK147676; BAE28067.1; -; mRNA.
DR   EMBL; AK157792; BAE34200.1; -; mRNA.
DR   EMBL; BC007466; AAH07466.1; -; mRNA.
DR   CCDS; CCDS25784.1; -. [O88508-2]
DR   CCDS; CCDS36397.1; -. [O88508-1]
DR   RefSeq; NP_001258682.1; NM_001271753.1. [O88508-1]
DR   RefSeq; NP_031898.1; NM_007872.4. [O88508-1]
DR   RefSeq; NP_714965.1; NM_153743.4. [O88508-2]
DR   RefSeq; XP_006515016.1; XM_006514953.2. [O88508-1]
DR   RefSeq; XP_006515017.1; XM_006514954.2. [O88508-1]
DR   RefSeq; XP_006515018.1; XM_006514955.2. [O88508-1]
DR   RefSeq; XP_006515019.1; XM_006514956.2. [O88508-1]
DR   RefSeq; XP_011242111.1; XM_011243809.1. [O88508-1]
DR   RefSeq; XP_011242112.1; XM_011243810.1. [O88508-1]
DR   UniGene; Mm.470389; -.
DR   UniGene; Mm.5001; -.
DR   PDB; 3SW9; X-ray; 3.05 A; P/Q=39-50.
DR   PDB; 3SWC; X-ray; 2.33 A; P/Q=39-50.
DR   PDBsum; 3SW9; -.
DR   PDBsum; 3SWC; -.
DR   ProteinModelPortal; O88508; -.
DR   SMR; O88508; 279-421, 469-908.
DR   BioGrid; 199261; 18.
DR   DIP; DIP-38005N; -.
DR   IntAct; O88508; 10.
DR   MINT; MINT-2521021; -.
DR   STRING; 10090.ENSMUSP00000020991; -.
DR   ChEMBL; CHEMBL3108652; -.
DR   REBASE; 3747; M.MmuDnmt3A.
DR   PhosphoSite; O88508; -.
DR   MaxQB; O88508; -.
DR   PaxDb; O88508; -.
DR   PRIDE; O88508; -.
DR   Ensembl; ENSMUST00000020991; ENSMUSP00000020991; ENSMUSG00000020661. [O88508-1]
DR   Ensembl; ENSMUST00000111186; ENSMUSP00000106817; ENSMUSG00000020661. [O88508-2]
DR   Ensembl; ENSMUST00000172689; ENSMUSP00000133543; ENSMUSG00000020661. [O88508-2]
DR   Ensembl; ENSMUST00000174817; ENSMUSP00000134009; ENSMUSG00000020661. [O88508-1]
DR   GeneID; 13435; -.
DR   KEGG; mmu:13435; -.
DR   UCSC; uc007mxb.1; mouse. [O88508-1]
DR   CTD; 1788; -.
DR   MGI; MGI:1261827; Dnmt3a.
DR   eggNOG; NOG70699; -.
DR   GeneTree; ENSGT00390000008341; -.
DR   HOGENOM; HOG000230875; -.
DR   HOVERGEN; HBG051381; -.
DR   InParanoid; O88508; -.
DR   KO; K17398; -.
DR   OMA; YTEMWVE; -.
DR   OrthoDB; EOG7MWGW6; -.
DR   PhylomeDB; O88508; -.
DR   TreeFam; TF329039; -.
DR   BRENDA; 2.1.1.37; 3474.
DR   Reactome; REACT_298576; PRC2 methylates histones and DNA.
DR   Reactome; REACT_319868; RMTs methylate histone arginines.
DR   Reactome; REACT_351456; DNA methylation.
DR   ChiTaRS; Dnmt3a; mouse.
DR   NextBio; 283867; -.
DR   PRO; PR:O88508; -.
DR   Proteomes; UP000000589; Chromosome 12.
DR   Bgee; O88508; -.
DR   CleanEx; MM_DNMT3A; -.
DR   ExpressionAtlas; O88508; baseline and differential.
DR   Genevisible; O88508; MM.
DR   GO; GO:0000775; C:chromosome, centromeric region; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; ISS:UniProtKB.
DR   GO; GO:0000791; C:euchromatin; ISS:UniProtKB.
DR   GO; GO:0000792; C:heterochromatin; IDA:MGI.
DR   GO; GO:0005720; C:nuclear heterochromatin; IDA:MGI.
DR   GO; GO:0016363; C:nuclear matrix; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; ISO:MGI.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0001741; C:XY body; IDA:MGI.
DR   GO; GO:0003682; F:chromatin binding; IDA:MGI.
DR   GO; GO:0003886; F:DNA (cytosine-5-)-methyltransferase activity; ISS:UniProtKB.
DR   GO; GO:0051718; F:DNA (cytosine-5-)-methyltransferase activity, acting on CpG substrates; IEA:Ensembl.
DR   GO; GO:0051719; F:DNA (cytosine-5-)-methyltransferase activity, acting on CpN substrates; TAS:Reactome.
DR   GO; GO:0003677; F:DNA binding; ISS:UniProtKB.
DR   GO; GO:0042802; F:identical protein binding; ISO:MGI.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0008168; F:methyltransferase activity; TAS:MGI.
DR   GO; GO:0045322; F:unmethylated CpG binding; IEA:Ensembl.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0090116; P:C-5 methylation of cytosine; ISO:MGI.
DR   GO; GO:0071230; P:cellular response to amino acid stimulus; IDA:MGI.
DR   GO; GO:0071361; P:cellular response to ethanol; IEA:Ensembl.
DR   GO; GO:0071456; P:cellular response to hypoxia; IEA:Ensembl.
DR   GO; GO:0006306; P:DNA methylation; ISS:UniProtKB.
DR   GO; GO:0043045; P:DNA methylation involved in embryo development; IMP:UniProtKB.
DR   GO; GO:0043046; P:DNA methylation involved in gamete generation; IMP:UniProtKB.
DR   GO; GO:0010424; P:DNA methylation on cytosine within a CG sequence; IEA:Ensembl.
DR   GO; GO:0097284; P:hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0044027; P:hypermethylation of CpG island; IDA:BHF-UCL.
DR   GO; GO:0010216; P:maintenance of DNA methylation; TAS:BHF-UCL.
DR   GO; GO:0006346; P:methylation-dependent chromatin silencing; IDA:MGI.
DR   GO; GO:0000278; P:mitotic cell cycle; IEA:Ensembl.
DR   GO; GO:0000122; P:negative regulation of transcription from RNA polymerase II promoter; IDA:MGI.
DR   GO; GO:0030182; P:neuron differentiation; IEA:Ensembl.
DR   GO; GO:0010942; P:positive regulation of cell death; IEA:Ensembl.
DR   GO; GO:0006349; P:regulation of gene expression by genetic imprinting; IDA:BHF-UCL.
DR   GO; GO:0036276; P:response to antidepressant; IEA:Ensembl.
DR   GO; GO:0042220; P:response to cocaine; IEA:Ensembl.
DR   GO; GO:0032355; P:response to estradiol; IEA:Ensembl.
DR   GO; GO:0010212; P:response to ionizing radiation; IEA:Ensembl.
DR   GO; GO:0010288; P:response to lead ion; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0033189; P:response to vitamin A; IEA:Ensembl.
DR   GO; GO:0046498; P:S-adenosylhomocysteine metabolic process; IEA:Ensembl.
DR   GO; GO:0046499; P:S-adenosylmethioninamine metabolic process; IEA:Ensembl.
DR   GO; GO:0007283; P:spermatogenesis; IMP:MGI.
DR   GO; GO:0006351; P:transcription, DNA-templated; IEA:UniProtKB-KW.
DR   Gene3D; 3.40.50.150; -; 1.
DR   InterPro; IPR025766; ADD.
DR   InterPro; IPR018117; C5_DNA_meth_AS.
DR   InterPro; IPR001525; C5_MeTfrase.
DR   InterPro; IPR030487; DNMT3A.
DR   InterPro; IPR000313; PWWP_dom.
DR   InterPro; IPR029063; SAM-dependent_MTases.
DR   PANTHER; PTHR23068:SF10; PTHR23068:SF10; 1.
DR   Pfam; PF00855; PWWP; 1.
DR   SMART; SM00293; PWWP; 1.
DR   SUPFAM; SSF53335; SSF53335; 1.
DR   PROSITE; PS51533; ADD; 1.
DR   PROSITE; PS00094; C5_MTASE_1; 1.
DR   PROSITE; PS50812; PWWP; 1.
DR   PROSITE; PS51679; SAM_MT_C5; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative promoter usage; Chromatin regulator;
KW   Complete proteome; Cytoplasm; DNA-binding; Metal-binding;
KW   Methyltransferase; Nucleus; Phosphoprotein; Reference proteome;
KW   Repressor; S-adenosyl-L-methionine; Transcription;
KW   Transcription regulation; Transferase; Ubl conjugation; Zinc;
KW   Zinc-finger.
FT   CHAIN         1    908       DNA (cytosine-5)-methyltransferase 3A.
FT                                /FTId=PRO_0000088044.
FT   DOMAIN      288    346       PWWP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00162}.
FT   DOMAIN      478    610       ADD. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00865}.
FT   DOMAIN      630    908       SAM-dependent MTase C5-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU01016}.
FT   ZN_FING     489    519       GATA-type; atypical.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00865}.
FT   ZN_FING     530    586       PHD-type; atypical. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00865}.
FT   REGION      195    399       Interaction with DNMT1 and DNMT3B.
FT                                {ECO:0000250}.
FT   REGION      490    582       Interaction with the PRC2/EED-EZH2
FT                                complex.
FT   REGION      637    641       S-adenosyl-L-methionine binding.
FT                                {ECO:0000250}.
FT   REGION      682    684       S-adenosyl-L-methionine binding.
FT                                {ECO:0000250}.
FT   REGION      887    889       S-adenosyl-L-methionine binding.
FT                                {ECO:0000250}.
FT   ACT_SITE    706    706       {ECO:0000255|PROSITE-ProRule:PRU01016,
FT                                ECO:0000255|PROSITE-ProRule:PRU10018}.
FT   BINDING     660    660       S-adenosyl-L-methionine. {ECO:0000250}.
FT   MOD_RES     102    102       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Y6K1}.
FT   MOD_RES     239    239       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Y6K1}.
FT   MOD_RES     251    251       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9Y6K1}.
FT   MOD_RES     257    257       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:Q9Y6K1}.
FT   VAR_SEQ       1    219       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:12138111,
FT                                ECO:0000303|PubMed:16141072}.
FT                                /FTId=VSP_009423.
FT   MUTAGEN     302    303       WP->ST: Prevents accumulation in
FT                                pericentric heterochromatin.
FT                                {ECO:0000269|PubMed:15456878}.
FT   MUTAGEN     636    636       F->A: Reduces activity about 20-fold.
FT                                Loss of substrate binding.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     660    660       E->A: Reduces activity about 15-fold.
FT                                Loss of substrate binding.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     682    682       D->A: Strongly reduces substrate binding.
FT                                No effect on activity.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     705    706       PC->VD: No effect on localization.
FT                                {ECO:0000269|PubMed:15456878}.
FT   MUTAGEN     706    706       C->A: Reduces activity about 5-fold.
FT                                Reduces DNA-binding capacity.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     707    707       N->Q: Reduces activity about 3-fold.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     710    710       S->A: No effect on activity.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     716    716       R->A: Reduces activity about 30-fold.
FT                                Reduces DNA-binding capacity.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     717    717       K->A: Reduces activity about 3-fold.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     728    728       F->A: Loss of activity du to the
FT                                incapacity to bind the regulatory subunit
FT                                DNMT3L. {ECO:0000269|PubMed:17713477}.
FT   MUTAGEN     752    752       E->A: Reduces activity about 10-fold.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     753    753       N->A: Reduces activity about 10-fold.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     788    788       R->A: Reduces activity about 15-fold.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     827    827       R->A: Reduces activity about 2-fold.
FT                                Reduces DNA-binding capacity.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     832    832       R->A: Reduces DNA-binding capacity. No
FT                                effect on activity.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     878    878       R->A: Reduces activity about 6-fold.
FT                                Reduces DNA-binding capacity.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     881    881       R->A: Loss of activity. Strongly reduces
FT                                substrate binding.
FT                                {ECO:0000269|PubMed:16472822}.
FT   MUTAGEN     883    883       R->A: Reduces activity about 3-fold.
FT                                Reduces DNA-binding capacity.
FT                                {ECO:0000269|PubMed:16472822}.
FT   CONFLICT    151    151       Q -> P (in Ref. 4; AAH07466).
FT                                {ECO:0000305}.
FT   CONFLICT    775    775       M -> T (in Ref. 3; BAB28644).
FT                                {ECO:0000305}.
FT   CONFLICT    781    781       V -> G (in Ref. 3; BAB28644).
FT                                {ECO:0000305}.
FT   CONFLICT    791    791       W -> R (in Ref. 3; BAB28644).
FT                                {ECO:0000305}.
FT   CONFLICT    809    809       L -> P (in Ref. 3; BAB28644).
FT                                {ECO:0000305}.
FT   CONFLICT    904    904       Y -> I (in Ref. 3; BAB28644).
FT                                {ECO:0000305}.
SQ   SEQUENCE   908 AA;  101672 MW;  5F98D5A8092C84A5 CRC64;
     MPSSGPGDTS SSSLEREDDR KEGEEQEENR GKEERQEPSA TARKVGRPGR KRKHPPVESS
     DTPKDPAVTT KSQPMAQDSG PSDLLPNGDL EKRSEPQPEE GSPAAGQKGG APAEGEGTET
     PPEASRAVEN GCCVTKEGRG ASAGEGKEQK QTNIESMKME GSRGRLRGGL GWESSLRQRP
     MPRLTFQAGD PYYISKRKRD EWLARWKREA EKKAKVIAVM NAVEENQASG ESQKVEEASP
     PAVQQPTDPA SPTVATTPEP VGGDAGDKNA TKAADDEPEY EDGRGFGIGE LVWGKLRGFS
     WWPGRIVSWW MTGRSRAAEG TRWVMWFGDG KFSVVCVEKL MPLSSFCSAF HQATYNKQPM
     YRKAIYEVLQ VASSRAGKLF PACHDSDESD SGKAVEVQNK QMIEWALGGF QPSGPKGLEP
     PEEEKNPYKE VYTDMWVEPE AAAYAPPPPA KKPRKSTTEK PKVKEIIDER TRERLVYEVR
     QKCRNIEDIC ISCGSLNVTL EHPLFIGGMC QNCKNCFLEC AYQYDDDGYQ SYCTICCGGR
     EVLMCGNNNC CRCFCVECVD LLVGPGAAQA AIKEDPWNCY MCGHKGTYGL LRRREDWPSR
     LQMFFANNHD QEFDPPKVYP PVPAEKRKPI RVLSLFDGIA TGLLVLKDLG IQVDRYIASE
     VCEDSITVGM VRHQGKIMYV GDVRSVTQKH IQEWGPFDLV IGGSPCNDLS IVNPARKGLY
     EGTGRLFFEF YRLLHDARPK EGDDRPFFWL FENVVAMGVS DKRDISRFLE SNPVMIDAKE
     VSAAHRARYF WGNLPGMNRP LASTVNDKLE LQECLEHGRI AKFSKVRTIT TRSNSIKQGK
     DQHFPVFMNE KEDILWCTEM ERVFGFPVHY TDVSNMSRLA RQRLLGRSWS VPVIRHLFAP
     LKEYFACV
//
